NeoGenomics Reports Revenue of $18.2 Million and Adjusted EBITDA of $1.7 million for the First Quarter
Press Release
Read More
NeoGenomics Announces Next Generation Sequencing Tests for Solid Tumor Cancers and Myelodysplastic Syndrome
Press Release
Read More
Diagnostic and prognostic scoring system for prostate cancer using urine and plasma biomarkers
Literature
Read More
NeoGenomics Reports Record Revenue of $18.3 Million, Adjusted EBITDA of $2.7 Million and Net Income of $0.02 per Share for the Fourth Quarter 2013
Press Release
Read More
NeoGenomics Launches 22 New Cancer Genomic Tests Designed for Actionable Profiling of Various Hematologic and Solid Cancers
Press Release
Read More
Characterization of diverse immune cell types in single cancer tissue specimens using hyper-plexed in situ immunofluorescence staining technology
Literature
Read More
NeoGenomics Schedules its Q4 2013 and Full Year 2013 Earnings Release for February 19, 2014
Press Release
Read More